Pharmacokinetics modeling of exogenous glucagon in Type 1 diabetes mellitus patients

Diabetes Technology and Therapeutics

Volumn 15, Issue 11, 2013, Pages 935-941

  Lv, Dayu ^a   Breton, Marc D ^a   Farhy, Leon S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON;

ANALYTICAL PARAMETERS; ARTICLE; CONTROL STRATEGY; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; GLUCAGON RELEASE; HALF LIFE TIME; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MATHEMATICAL MODEL; PLASMA CLEARANCE; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; ALGORITHMS; BAYES THEOREM; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MONITORING, PHYSIOLOGIC; PANCREAS, ARTIFICIAL;

EID: 84887056732     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0150     Document Type: Article

References (26)

1. Cryer PE: The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176.
2. Taborsky GJ Jr: The physiology of glucagon. J Diabetes Sci Technol 2010;4:1338-1344.
3. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK: Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
4. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER: A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27.
5. Ward WK, Castle JR, El Youssef J: Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia. J Diabetes Sci Technol 2012;5:1373-1380.
6. Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R: Glucose-responsive insulin and glucagon delivery (dualhormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185:297-305.
7. Cryer PE: Hypoglycemia risk reduction in type 1 diabetes. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S412-S423.
8. Cryer PE: Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14: 750-756.
9. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW: The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-1107.
10. Kovatchev BP, Breton M, Dalla Man C, Cobelli C: In silico preclinical trials: a proof of concept in closed-loop of type 1 diabetes. J Diabetes Sci Technol 2009;3:44-55.
11. Sorensen J: A physiological model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes [PhD thesis]. Cambridge, MA: Massachusetts Institute of Technology, 1985.
12. Markakis MG, Mitsis GD, Marmarelis VZ: Computational study of an augmented minimal model for glycaemia control. Conf Proc IEEE Eng Med Biol Soc 2008;2008:5445-5448.
13. Marmaerlis VZ: Modeling methodology for nonlinear physiological systems. Ann Biomed Eng 1997;25:239-251.
14. Dalla Man C, Rizza RA, Cobelli C: Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng 2007; 54:1740-1749.
15. Fisher M, Sherwin RS, Hendler R, Felig P: Kinetics of glucagon in man: effects of starvation. Proc Natl Acad Sci USA 1976;73:1735-1739.
16. Swann J, Hammes G: Self-association of glucagon. Equilibrium studies. Biochemistry 1969;8:41-58.
17. Chou P, Fasman G: The conformation of glucagon: predictions and consequences. Biochemistry 1975;14:2536-2541.
18. Nucci G, Cobelli C: Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed 2000; 62:249-257.
19. Dalla Man C, Raimondo DM, Rizza RA, Cobelli C: GIM, simulation software of meal glucose-insulin model. J Diabetes Sci Technol 2007;1:323-330.
20. www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/ CPS-%20(General%20Monographs-%20G)/GLUCAGON%20INJECTION.html (accessed January 6, 2013).
21. Alford FP, Bloom SR, Nabarro JDN: Glucagon metabolism in man. Studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects. J Clin Endocrinol Metab 1976;42:830-838.
22. Bergman RN, Ziya Ider Y, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-E677.
23. Lorenzi M, Bohannon N, Tsalikian E, Karam JH: Duration of type 1 diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia. West J Med 1984;141:467-471.
24. Taborsky G Jr, Mundinger T: Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012;153:1055-1062.
25. Beall C, Ashford ML, McCrimmon RJ: The physiology and pathophysiology of the neural control of the counterregulatory response. Am J Physiol Regul Integr Comp Physiol 2012;302:R215-R223.
26. Micheletto F, Dalla Man C, Kovatchev BP, Cobelli C: The updated University of Virginia/Padova type 1 diabetes simulator [abstract A94]. J Diabetes Sci Technol 2012;7:281-284.